Silo Pharma wins European patent for PTSD prevention therapy SPC-15

Reuters2026/08/10 12:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Silo Pharma won a European patent for its lead PTSD candidate SPC-15, a preventative intranasal, nose-to-brain therapy targeting stress-induced psychiatric disorders.
The EPO granted EP3952852, covering methods using selected 5-HT4 receptor agonists administered before extreme stress exposure to prevent fear or depressive-like behavior.
The company holds an exclusive license from Columbia University for the European patent, supporting its plan to develop and commercialize SPC-15 globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100815PRIMZONEFULLFEED9806622) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Silo Pharma wins European patent for PTSD prevention therapy SPC-15

You may also like

Crypto prices